Stock Track | Philip Morris Soars 5.03% Intraday on Strong Q2 Earnings Beat and FDA Authorization for ZYN

Stock Track
07/22

Philip Morris International's stock surged 5.03% during intraday trading on Wednesday, reflecting significant investor optimism.

The sharp rise follows the company's release of better-than-expected second-quarter results, with adjusted earnings per share of $2.20 beating the IBES estimate of $2.04 and net revenue of $11.20 billion surpassing the consensus forecast of $10.63 billion. Concurrently, a major regulatory catalyst emerged as the U.S. Food and Drug Administration issued Modified Risk Tobacco Product orders for 20 variants of the company's ZYN nicotine pouches earlier this month, authorizing reduced-risk marketing claims.

Positive analyst sentiment also contributed to the bullish momentum, with BTIG initiating coverage on the stock with a Buy rating and a $216 price target. The company noted that consumer demand for its products has remained resilient despite geopolitical tensions, and it is ramping up investment to grow its smoke-free ZYN business.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10